Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab q6w for treatment-naive PCV (single-arm, China)
ChiCTR2500110883Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2025
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brolucizumab in polypoidal choroidal vasculopathy (PCV), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete polyp regression rate at week 16. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
brolucizumab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on ChiCTR2500110883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110883.